Investors - UCB
UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease. This ambition fuels our purpose: creating value in the …
Full year financial results - UCB
UCB will publish its 2021 Full-Year Financial Results on Thursday, 24th of February 2022. 07.00 CET Publication of press release and management report; 14.00 CET Presentation for …
Download center - UCB
UCB and Ailux Biologics Join Forces to Transform Biologics Research Page Publications - A dedicated space where we share a collection of our scientific peer-reviewed...
UCB
At UCB, we believe that everyone deserves to live the best life that they can. That’s why - as a global biopharmaceutical leader - we’re focused on creating valuable solutions that improve …
Performance - UCB
Dec 31, 2024 · The 2024 investing activities include mainly the proceeds (net of cash disposed) from the divestment of UCB’s mature neurology and allergy business in China for € 619 million …
Corporate Governance - UCB
Find out about UCB shareholders, their transparency notifications and our shareholder meetings on the dedicated webpage.
Half-year results 2024: strong start into UCB’s decade of growth
Jul 24, 2024 · Our intensified investments and exploration of new growth avenues have set UCB on a path of strong growth. Experiencing double-digit growth – after double-digit decline in the …
Careers at UCB | UCB jobs
Let's push the boundaries together and make the most of your talents. Find available jobs in fields like Finance, Medical & Clinical, Sales & Marketing and more
UCB’s Board of Directors appoints Jonathan Peacock as new Chair
Mar 9, 2023 · During its meeting on March 8, 2023 UCB’s Board of Directors elected Jonathan Peacock, currently Independent Director and Chair of the Audit Committee at UCB, as Chair of …
Press releases - UCB
Mar 28, 2025 · UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025 Read More